Edition:
India

Intellia Therapeutics Inc (NTLA.OQ)

NTLA.OQ on NASDAQ Stock Exchange Global Market

19.43USD
19 Jan 2018
Change (% chg)

$-0.52 (-2.61%)
Prev Close
$19.95
Open
$19.94
Day's High
$20.00
Day's Low
$19.12
Volume
274,882
Avg. Vol
266,903
52-wk High
$33.20
52-wk Low
$10.83

Latest Key Developments (Source: Significant Developments)

Intellia Therapeutics Names John Leonard, M.D., President And CEO
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Intellia Therapeutics Inc ::INTELLIA THERAPEUTICS NAMES JOHN LEONARD, M.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER.INTELLIA THERAPEUTICS INC - LEONARD SUCCEEDS NESSAN BERMINGHAM.  Full Article

Intellia Therapeutics prices public offering of 6.3 mln shares at $24 per share
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - Intellia Therapeutics Inc :Intellia Therapeutics announces pricing of public offering of common stock.Says ‍priced public offering of 6.3 million shares of its common stock at a public offering price of $24.00 per share​.  Full Article

Intellia Therapeutics announces proposed public offering of common stock
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Intellia Therapeutics Inc NTLA.O:Intellia therapeutics announces proposed public offering of common stock.Intellia therapeutics inc - ‍has commenced an underwritten public offering of $150 million of its common stock​.  Full Article

Intellia Therapeutics Q3 loss per share $‍0.44​
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Intellia Therapeutics Inc ::Intellia therapeutics announces third quarter 2017 financial results.Q3 collaboration revenue $7.3 million versus $4.9 million.Q3 revenue view $5.9 million -- Thomson Reuters I/B/E/S.Says ‍well-tolerated safety profile observed for CRISPR/Cas9.Qtrly loss per share $‍0.44​.Q3 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.  Full Article

Intellia Therapeutics Q3 revenue $65 mln
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Intellia Therapeutics Inc -:Intellia Therapeutics announces third quarter 2017 financial results.Q3 revenue $65 million.Q3 revenue view $5.9 million -- Thomson Reuters I/B/E/S.Says ‍well-tolerated safety profile observed for CRISPR/CAS9.  Full Article

Atlas Venture Fund reports 12.3 pct stake in Intellia Therapeutics
Friday, 10 Feb 2017 

Atlas Venture Fund IX, L.P:Atlas Venture Fund IX, L.P. reports a 12.3 percent passive stake in Intellia Therapeutics Inc as of December 31, 2016 -sec filing.  Full Article

Intellia Therapeutics qtrly net loss of $6.9 mln vs net loss of $3 mln in Q2 2015
Friday, 5 Aug 2016 

Intellia Therapeutics Inc : Intellia therapeutics reports financial results for second quarter 2016 . Collaboration revenue was $4.2 million in q2 2016, compared to $1.4 million in same period of 2015 .Qtrly net loss of $6.9 million versus net loss of $3 million in q2 2015.  Full Article

Orbimed Advisors reports 7.40% stake in Intellia Therapeutics
Saturday, 21 May 2016 

Intellia Therapeutics Inc :Orbimed Advisors LLC reports 7.40% stake in Intellia Therapeutics as of May 11, 2016 - sec filing.  Full Article

Regeneron Pharmaceuticals reports 7.7 pct passive stake in Intellia Therapeutics
Thursday, 12 May 2016 

Regeneron Pharmaceuticals Inc:Regeneron Pharmaceuticals Inc reports 7.7 pct passive stake in Intellia Therapeutics Inc as of May 11 - SEC Filing.  Full Article

Intellia Therapeutics shares open 22.2 pct above IPO price in debut
Friday, 6 May 2016 

: Intellia Therapeutics Inc shares open at $22.00 in market debut, above IPO price of $18.00 Further company coverage: [NTLA.O] ((Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780;)).  Full Article

BRIEF-Intellia Therapeutics Names John Leonard, M.D., President And CEO

* INTELLIA THERAPEUTICS NAMES JOHN LEONARD, M.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER